SubsidieMeestersNext-generation heart bypass grafts to naturally restore cardiovascular function.
Xeltis aims to clinically validate a restorative vascular graft (XABG) to treat coronary artery disease without vein harvesting, enhancing patient outcomes and reducing healthcare costs.
Projectdetails
Introduction
Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis.
Current Treatment
Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting patients' veins from the legs as grafts.
Complications of Current Treatment
- This collection affects patients, causing chronic pain and costly complications.
- It also has a high failure rate, with over 20% of implants occluded after 1 year.
Innovative Solution
Xeltis has developed a unique restorative vascular graft (XABG) that eliminates the need for vein harvesting.
Advantages of XABG
- The implant provides a homing structure for cells in which cardiac and vascular tissues can be naturally restored.
- This leads to related advantages and benefits for patients and the healthcare system.
Progress and Future Plans
We have proven our technology in first niche applications, as well as completed pre-clinical studies successfully for XABG.
Next Steps
Now, we plan to perform a full clinical validation to obtain a CE mark in Europe and start market deployment and commercial up-scaling.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.481.701 |
| Totale projectbegroting | € 4.205.283 |
Tijdlijn
| Startdatum | 1-12-2022 |
| Einddatum | 30-11-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- XELTIS BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Blood as energy source to power smart cardiac devicesThe BLOOD2POWER project aims to develop energy-harvesting vascular grafts using triboelectric nanogenerators to monitor performance and prevent failure through wireless data transmission. | EIC Pathfinder | € 2.885.525 | 2023 | Details |
XELENA Heart BypassXeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten. | MIT R&D Samenwerking | € 318.850 | 2020 | Details |
BIOPASSHet BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten. | MIT R&D Samenwerking | € 349.265 | 2017 | Details |
Blood as energy source to power smart cardiac devices
The BLOOD2POWER project aims to develop energy-harvesting vascular grafts using triboelectric nanogenerators to monitor performance and prevent failure through wireless data transmission.
XELENA Heart Bypass
Xeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten.
BIOPASS
Het BIOPASS-project ontwikkelt een minimaal-invasieve bypasstechniek met bio afbreekbare donorvaten om complicaties te verminderen en herstel te versnellen, met als doel een innovatieve oplossing voor hartpatiënten.